{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:26:27Z","timestamp":1793651187539,"version":"4.5.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s10741-014-9462-7","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T12:37:30Z","timestamp":1416573450000},"page":"163-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs"],"prefix":"10.1007","volume":"20","author":[{"given":"Adam","family":"Casta\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Drachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,19]]},"reference":[{"issue":"4","key":"9462_CR1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","volume":"60","author":"K Dharmarajan","year":"2012","unstructured":"Dharmarajan K, Maurer MS (2012) Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc 60(4):765\u2013774","journal-title":"J Am Geriatr Soc"},{"issue":"13","key":"9462_CR2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C et al (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203\u20131212","journal-title":"Circulation"},{"issue":"4","key":"9462_CR3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","volume":"158","author":"LH Connors","year":"2009","unstructured":"Connors LH et al (2009) Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 158(4):607\u2013614","journal-title":"Am Heart J"},{"issue":"2","key":"9462_CR4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s004390050199","volume":"98","author":"DR Jacobson","year":"1996","unstructured":"Jacobson DR et al (1996) Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 98(2):236\u2013238","journal-title":"Hum Genet"},{"issue":"2","key":"9462_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/13506129.2010.483114","volume":"17","author":"R Hornsten","year":"2010","unstructured":"Hornsten R et al (2010) Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 17(2):63\u201368","journal-title":"Amyloid"},{"issue":"8","key":"9462_CR6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/ejhg.2010.36","volume":"18","author":"B Bonaiti","year":"2010","unstructured":"Bonaiti B et al (2010) TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? Eur J Hum Genet 18(8):948\u2013952","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"9462_CR7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/13506120701815373","volume":"15","author":"C Rapezzi","year":"2008","unstructured":"Rapezzi C et al (2008) Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 15(1):40\u201348","journal-title":"Amyloid"},{"issue":"3","key":"9462_CR8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/13506120600876849","volume":"13","author":"OB Suhr","year":"2006","unstructured":"Suhr OB et al (2006) Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid 13(3):154\u2013159","journal-title":"Amyloid"},{"issue":"5","key":"9462_CR9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","volume":"235","author":"O Suhr","year":"1994","unstructured":"Suhr O et al (1994) Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 235(5):479\u2013485","journal-title":"J Intern Med"},{"issue":"1","key":"9462_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB (2013) THAOS\u2014the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29(1):63\u201376","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"9462_CR11","doi-asserted-by":"crossref","first-page":"E1244","DOI":"10.1016\/S0735-1097(13)61244-9","volume":"61","author":"MS Maurer","year":"2013","unstructured":"Maurer MS et al (2013) Cardiac biomarkers in patients with transthyretin amyloidosis as documented in THAOS: the transthyretin amyloidosis survey. J Am Coll Cardiol 61(10):E1244\u2013E1244","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9462_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","volume":"9","author":"RC Givens","year":"2013","unstructured":"Givens RC et al (2013) Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health 9(2):229\u2013235","journal-title":"Aging Health"},{"issue":"2","key":"9462_CR13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","volume":"216","author":"E Ihse","year":"2008","unstructured":"Ihse E et al (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216(2):253\u2013261","journal-title":"J Pathol"},{"key":"9462_CR14","doi-asserted-by":"crossref","unstructured":"Khella S, Drachman B, Divito P, Polydefkis M, Brannagan T, Judge D, Maurer MS (2013) Neurologic involvement in Val122Ile familial amyloidosis. In: IXth international symposium on familial amyloid polyneuropathy; VIIIth international symposium on liver transplantation in familial amyloid polyneuropathy, Rio de Janeiro, Brazil","DOI":"10.1212\/WNL.82.10_supplement.P1.026"},{"issue":"12","key":"9462_CR15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","volume":"165","author":"B Ng","year":"2005","unstructured":"Ng B et al (2005) Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165(12):1425\u20131429","journal-title":"Arch Intern Med"},{"issue":"2","key":"9462_CR16","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","volume":"2","author":"JH Pinney","year":"2013","unstructured":"Pinney JH et al (2013) Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2(2):e000098","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"9462_CR17","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","volume":"129","author":"CC Quarta","year":"2014","unstructured":"Quarta CC et al (2014) Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129(18):1840\u20131849","journal-title":"Circulation"},{"issue":"14","key":"9462_CR18","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","volume":"104","author":"R Liao","year":"2001","unstructured":"Liao R et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104(14):1594\u20131597","journal-title":"Circulation"},{"issue":"1","key":"9462_CR19","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","volume":"305","author":"S Mishra","year":"2013","unstructured":"Mishra S et al (2013) Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 305(1):H95\u2013H103","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"9462_CR20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL et al (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS). Am Heart J 164(2):222\u2013228 e1","journal-title":"Am Heart J"},{"issue":"13","key":"9462_CR21","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112(13):2047\u20132060","journal-title":"Circulation"},{"issue":"21","key":"9462_CR22","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","volume":"116","author":"D Feng","year":"2007","unstructured":"Feng D et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420\u20132426","journal-title":"Circulation"},{"issue":"6","key":"9462_CR23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ana.10552","volume":"53","author":"M Berghoff","year":"2003","unstructured":"Berghoff M et al (2003) Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Ann Neurol 53(6):725\u2013730","journal-title":"Ann Neurol"},{"issue":"10","key":"9462_CR24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.1983.03330340064034","volume":"249","author":"RA Yood","year":"1983","unstructured":"Yood RA et al (1983) Bleeding manifestations in 100 patients with amyloidosis. JAMA 249(10):1322\u20131324","journal-title":"JAMA"},{"issue":"18","key":"9462_CR25","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","volume":"119","author":"D Feng","year":"2009","unstructured":"Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490\u20132497","journal-title":"Circulation"},{"issue":"5","key":"9462_CR26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","volume":"74","author":"S Dubrey","year":"1995","unstructured":"Dubrey S et al (1995) Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 74(5):541\u2013544","journal-title":"Br Heart J"},{"issue":"2","key":"9462_CR27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0002-9149(00)00870-5","volume":"86","author":"L Murphy","year":"2000","unstructured":"Murphy L, Falk RH (2000) Left atrial kinetic energy in AL amyloidosis: can it detect early dysfunction? Am J Cardiol 86(2):244\u2013246","journal-title":"Am J Cardiol"},{"issue":"2","key":"9462_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 137(2):263\u2013272","journal-title":"Chest"},{"issue":"1","key":"9462_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0735-1097(90)90183-P","volume":"15","author":"AL Klein","year":"1990","unstructured":"Klein AL et al (1990) Comprehensive doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 15(1):99\u2013108","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"9462_CR30","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/01.CIR.0000068313.67758.4F","volume":"107","author":"J Koyama","year":"2003","unstructured":"Koyama J, Ray-Sequin PA, Falk RH (2003) Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107(19):2446\u20132452","journal-title":"Circulation"},{"issue":"2","key":"9462_CR31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(02)01944-7","volume":"40","author":"DL King","year":"2002","unstructured":"King DL, El-Khoury Coffin L, Maurer MS (2002) Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography. J Am Coll Cardiol 40(2):325\u2013329","journal-title":"J Am Coll Cardiol"},{"key":"9462_CR32","doi-asserted-by":"crossref","unstructured":"Tendler AHA, Maurer MS (2013) Myocardial contraction fraction is superior to the myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with cardiac amyloidosis. In: IX international symposium on familial amyloidotic polyneuropathy (ISFAP) and the VIII international symposium on liver transplantation in familial amyloidotic polyneuropathy, Rio de Janeiro, Brazil","DOI":"10.3109\/13506129.2014.994202"},{"key":"9462_CR33","doi-asserted-by":"crossref","unstructured":"Damy T, Plante-Bordeneuve V, Karayal O, Mundayat R, Kristen AV (2013) Clinical and echocardiographic signs associated with increased interventricular thickness (IVST) due to TTR related amyloidosis. In: European Society of Cardiology, Amsterdam, Netherlands","DOI":"10.1093\/eurheartj\/eht309.P4233"},{"issue":"3","key":"9462_CR34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/lv.2000.6145","volume":"6","author":"OB Suhr","year":"2000","unstructured":"Suhr OB et al (2000) Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 6(3):263\u2013276","journal-title":"Liver Transpl"},{"key":"9462_CR35","unstructured":"Tsay DM, Maurer MS (2014) Biomarkers in ATTR cardiac amyloidosis (in submission)"},{"issue":"2","key":"9462_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S et al (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195\u2013201","journal-title":"Circ Cardiovasc Imaging"},{"key":"9462_CR37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","volume":"55","author":"JT Cassidy","year":"1961","unstructured":"Cassidy JT (1961) Cardiac amyloidosis. Two cases with digitalis sensitivity. Ann Intern Med 55:989\u2013994","journal-title":"Ann Intern Med"},{"issue":"5","key":"9462_CR38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/hrt.27.5.711","volume":"27","author":"A Pomerance","year":"1965","unstructured":"Pomerance A (1965) Senile cardiac amyloidosis. Br Heart J 27(5):711\u2013718","journal-title":"Br Heart J"},{"issue":"6","key":"9462_CR39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","volume":"63","author":"A Rubinow","year":"1981","unstructured":"Rubinow A, Skinner M, Cohen AS (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63(6):1285\u20131288","journal-title":"Circulation"},{"issue":"3","key":"9462_CR40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1542-474X.2008.00228.x","volume":"13","author":"U Wiklund","year":"2008","unstructured":"Wiklund U et al (2008) Abnormal heart rate variability and subtle atrial arrhythmia in patients with familial amyloidotic polyneuropathy. Ann Noninvasive Electrocardiol 13(3):249\u2013256","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"2","key":"9462_CR41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.22184","volume":"17","author":"S Okamoto","year":"2011","unstructured":"Okamoto S et al (2011) Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant). Liver Transpl 17(2):122\u2013128","journal-title":"Liver Transpl"},{"issue":"7","key":"9462_CR42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","volume":"9","author":"V Algalarrondo","year":"2012","unstructured":"Algalarrondo V et al (2012) Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 9(7):1069\u20131075","journal-title":"Heart Rhythm"},{"issue":"6","key":"9462_CR43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.hrthm.2008.04.015","volume":"5","author":"AE Epstein","year":"2008","unstructured":"Epstein AE et al (2008) ACC\/AHA\/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. Heart Rhythm 5(6):934\u2013955","journal-title":"Heart Rhythm"},{"issue":"2","key":"9462_CR44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijcard.2010.10.015","volume":"155","author":"Y Zhao","year":"2012","unstructured":"Zhao Y et al (2012) Left ventricular dyssynchrony is associated with reduced heart rate variability in familial amyloidotic polyneuropathy. Int J Cardiol 155(2):273\u2013278","journal-title":"Int J Cardiol"},{"issue":"2","key":"9462_CR45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","volume":"91","author":"SW Dubrey","year":"1998","unstructured":"Dubrey SW et al (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91(2):141\u2013157","journal-title":"QJM"},{"issue":"1","key":"9462_CR46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0735-1097(84)80436-2","volume":"3","author":"RH Falk","year":"1984","unstructured":"Falk RH, Rubinow A, Cohen AS (1984) Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 3(1):107\u2013113","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9462_CR47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","volume":"5","author":"AV Kristen","year":"2008","unstructured":"Kristen AV et al (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5(2):235\u2013240","journal-title":"Heart Rhythm"},{"issue":"8","key":"9462_CR48","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/clc.20389","volume":"32","author":"A Dhoble","year":"2009","unstructured":"Dhoble A et al (2009) Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol 32(8):E63\u2013E65","journal-title":"Clin Cardiol"},{"issue":"12","key":"9462_CR49","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/eurheartj\/ehp592","volume":"31","author":"G Lin","year":"2010","unstructured":"Lin G, Dispenzieri A, Brady PA (2010) Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 31(12):1538","journal-title":"Eur Heart J"},{"issue":"7","key":"9462_CR50","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","volume":"24","author":"G Lin","year":"2013","unstructured":"Lin G et al (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24(7):793\u2013798","journal-title":"J Cardiovasc Electrophysiol"},{"key":"9462_CR51","unstructured":"Garan AR, Kolluri S, Lombardo I, Maurer MS (2012) The prevalence of Holter abnormalities in ATTR cardiac amyloidosis. In: XIII international symposium on amyloidosis, Groningen, Netherlands"},{"issue":"1","key":"9462_CR52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","volume":"11","author":"BC Varr","year":"2014","unstructured":"Varr BC et al (2014) Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 11(1):158\u2013162","journal-title":"Heart Rhythm"},{"issue":"3","key":"9462_CR53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren G et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40(3):242\u2013246","journal-title":"Clin Genet"},{"issue":"8853","key":"9462_CR54","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren G et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341(8853):1113\u20131116","journal-title":"Lancet"},{"issue":"1","key":"9462_CR55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/13506120108993814","volume":"8","author":"E Jonsen","year":"2001","unstructured":"Jonsen E et al (2001) Early liver transplantation is essential for familial amyloidotic polyneuropathy patients\u2019 quality of life. Amyloid 8(1):52\u201357","journal-title":"Amyloid"},{"issue":"6","key":"9462_CR56","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1399-0004.1991.tb03117.x","volume":"40","author":"O Sandgren","year":"1991","unstructured":"Sandgren O et al (1991) Vitreous involvement in familial amyloidotic neuropathy: a genealogical and genetic study. Clin Genet 40(6):452\u2013460","journal-title":"Clin Genet"},{"issue":"3","key":"9462_CR57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0167-5273(83)90101-8","volume":"4","author":"BO Olofsson","year":"1983","unstructured":"Olofsson BO (1983) Cardiac involvement in familial amyloidosis with polyneuropathy. Int J Cardiol 4(3):379\u2013382","journal-title":"Int J Cardiol"},{"issue":"4","key":"9462_CR58","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/00365521.1984.12005756","volume":"19","author":"LE Steen","year":"1984","unstructured":"Steen LE, Ek BO (1984) Familial amyloidosis with polyneuropathy. Aspects of the relationship between gastrointestinal symptoms, EMG findings, and malabsorption studies. Scand J Gastroenterol 19(4):480\u2013486","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"9462_CR59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1432-2277.2008.00737.x","volume":"22","author":"M Bispo","year":"2009","unstructured":"Bispo M et al (2009) High incidence of thrombotic complications early after liver transplantation for familial amyloidotic polyneuropathy. Transpl Int 22(2):165\u2013171","journal-title":"Transpl Int"},{"issue":"12","key":"9462_CR60","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.lts.2003.09.016","volume":"9","author":"P Sharma","year":"2003","unstructured":"Sharma P et al (2003) Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl 9(12):1273\u20131280","journal-title":"Liver Transpl"},{"issue":"4","key":"9462_CR61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13506120701614032","volume":"14","author":"JJ Liepnieks","year":"2007","unstructured":"Liepnieks JJ, Benson MD (2007) Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 14(4):277\u2013282","journal-title":"Amyloid"},{"issue":"4","key":"9462_CR62","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","volume":"75","author":"JJ Liepnieks","year":"2010","unstructured":"Liepnieks JJ, Zhang LQ, Benson MD (2010) Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 75(4):324\u2013327","journal-title":"Neurology"},{"issue":"10","key":"9462_CR63","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/TP.0b013e31824b3749","volume":"93","author":"S Gustafsson","year":"2012","unstructured":"Gustafsson S et al (2012) Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 93(10):1017\u20131023","journal-title":"Transplantation"},{"issue":"1\u20132","key":"9462_CR64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0041-1345(96)00206-0","volume":"29","author":"A Furtado","year":"1997","unstructured":"Furtado A et al (1997) Sequential liver transplantation. Transplant Proc 29(1\u20132):467\u2013468","journal-title":"Transplant Proc"},{"issue":"2","key":"9462_CR65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/lt.500050204","volume":"5","author":"L Furtado","year":"1999","unstructured":"Furtado L et al (1999) Maximum sharing of cadaver liver grafts composite split and domino liver transplants. Liver Transpl Surg 5(2):157\u2013158","journal-title":"Liver Transpl Surg"},{"issue":"1\u20132","key":"9462_CR66","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0041-1345(00)02540-9","volume":"33","author":"L Tome","year":"2001","unstructured":"Tome L et al (2001) Sequential liver transplantation: 27 cases in 25 patients. Transplant Proc 33(1\u20132):1430\u20131432","journal-title":"Transplant Proc"},{"issue":"7","key":"9462_CR67","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/tri.12110","volume":"26","author":"FJ Bolte","year":"2013","unstructured":"Bolte FJ et al (2013) Evaluation of domino liver transplantations in Germany. Transpl Int 26(7):715\u2013723","journal-title":"Transpl Int"},{"issue":"2","key":"9462_CR68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3109\/13506129.2014.885894","volume":"21","author":"MM Abdelfatah","year":"2014","unstructured":"Abdelfatah MM, Hayman SR, Gertz MA (2014) Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy. Amyloid 21(2):136\u2013137","journal-title":"Amyloid"},{"issue":"2","key":"9462_CR69","first-page":"165","volume":"7","author":"R Conner","year":"1988","unstructured":"Conner R et al (1988) Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant 7(2):165\u2013167","journal-title":"J Heart Transplant"},{"issue":"11","key":"9462_CR70","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.healun.2004.08.025","volume":"24","author":"J Kpodonu","year":"2005","unstructured":"Kpodonu J et al (2005) Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 24(11):1763\u20131765","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"9462_CR71","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","volume":"7","author":"C Rapezzi","year":"2010","unstructured":"Rapezzi C et al (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 7(7):398\u2013408","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"9462_CR72","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MA, Kelly JW (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13(4):236\u2013249","journal-title":"Amyloid"},{"issue":"4","key":"9462_CR73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","volume":"56","author":"K Tojo","year":"2006","unstructured":"Tojo K et al (2006) Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 56(4):441\u2013449","journal-title":"Neurosci Res"},{"issue":"2\u20133","key":"9462_CR74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","volume":"421","author":"SM Johnson","year":"2012","unstructured":"Johnson SM et al (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421(2\u20133):185\u2013203","journal-title":"J Mol Biol"},{"issue":"5","key":"9462_CR75","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3700059","volume":"84","author":"SR Miller","year":"2004","unstructured":"Miller SR, Sekijima Y, Kelly JW (2004) Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84(5):545\u2013552","journal-title":"Lab Invest"},{"issue":"2","key":"9462_CR76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/jm030347n","volume":"47","author":"SL Adamski-Werner","year":"2004","unstructured":"Adamski-Werner SL et al (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 47(2):355\u2013374","journal-title":"J Med Chem"},{"issue":"7553","key":"9462_CR77","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM et al (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332(7553):1302\u20131308","journal-title":"BMJ"},{"issue":"6","key":"9462_CR78","first-page":"S17","volume":"20","author":"M Epstein","year":"2002","unstructured":"Epstein M (2002) Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J Hypertens Suppl 20(6):S17\u2013S23","journal-title":"J Hypertens Suppl"},{"issue":"11","key":"9462_CR79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0165-6147(99)01385-1","volume":"20","author":"LJ Marnett","year":"1999","unstructured":"Marnett LJ, Kalgutkar AS (1999) Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci 20(11):465\u2013469","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"9462_CR80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/bega.2001.0229","volume":"15","author":"JL Wallace","year":"2001","unstructured":"Wallace JL (2001) Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15(5):691\u2013703","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"8","key":"9462_CR81","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286(8):954\u2013959","journal-title":"JAMA"},{"issue":"6","key":"9462_CR82","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinte.160.6.777","volume":"160","author":"J Page","year":"2000","unstructured":"Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 160(6):777\u2013784","journal-title":"Arch Intern Med"},{"issue":"6","key":"9462_CR83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","volume":"18","author":"A Castano","year":"2012","unstructured":"Castano A et al (2012) Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 18(6):315\u2013319","journal-title":"Congest Heart Fail"},{"issue":"24","key":"9462_CR84","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310(24):2658\u20132667","journal-title":"JAMA"},{"key":"9462_CR85","unstructured":"Quarta CCF, Solomon RH, Suhr SD, Obici OB, Perlini L, Lindqvist S, Koyama P, Sekijima J, Zeldenrust Y, Yamashita SR, Horibata T, Miller Y, Gorevic F, Merlini P, Ando G, Ikeda Y, Ruberg S, Berk F (2014) The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: the diflunisal trial. In: International symposium on amyloidosis, Indianapolis, USA, pp 88\u201389"},{"issue":"24","key":"9462_CR86","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 109(24):9629\u20139634","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 4","key":"9462_CR87","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","volume":"99","author":"P Hammarstrom","year":"2002","unstructured":"Hammarstrom P et al (2002) Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99(Suppl 4):16427\u201316432","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"9462_CR88","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785\u2013792","journal-title":"Neurology"},{"issue":"6","key":"9462_CR89","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini G et al (2013) Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 6(6):1011\u20131020","journal-title":"J Cardiovasc Transl Res"},{"key":"9462_CR90","unstructured":"Maurer MS, JDP, Rosas GR, Mandel FS, Aarts J (2014) Interim analysis of long-term, open-label tafamidis treatment in transthyretin amyloid cardiomyopathy after up to 5\u00a0years of treatment. In: International symposium on amyloidosis, Indianapolis, USA"},{"key":"9462_CR91","unstructured":"Pfizer (2014) Safety and efficacy of tafamidis in patients with transthyretin cardiomyopathy (ATTR-ACT). Available from: http:\/\/www.clinicaltrials.gov\/show\/NCT01994889"},{"issue":"97","key":"9462_CR92","doi-asserted-by":"crossref","first-page":"97ra81","DOI":"10.1126\/scitranslmed.3002473","volume":"3","author":"MM Alhamadsheh","year":"2011","unstructured":"Alhamadsheh MM et al (2011) Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med 3(97):97ra81","journal-title":"Sci Transl Med"},{"issue":"24","key":"9462_CR93","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala SC et al (2013) AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA 110(24):9992\u20139997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6669","key":"9462_CR94","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806\u2013811","journal-title":"Nature"},{"issue":"6836","key":"9462_CR95","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM et al (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494\u2013498","journal-title":"Nature"},{"key":"9462_CR96","unstructured":"Delivery, A.R.R.C. (2012) Available from: http:\/\/www.alnylam.com\/capella\/roundtables\/rnai-roundtable-conjugate-delivery-dec-14\/"},{"issue":"11","key":"9462_CR97","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R et al (2013) Delivery materials for siRNA therapeutics. Nat Mater 12(11):967\u2013977","journal-title":"Nat Mater"},{"issue":"9","key":"9462_CR98","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369(9):819\u2013829","journal-title":"N Engl J Med"},{"issue":"2","key":"9462_CR99","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1074\/jbc.M008091200","volume":"276","author":"AM Bennekum van","year":"2001","unstructured":"van Bennekum AM et al (2001) Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice. J Biol Chem 276(2):1107\u20131113","journal-title":"J Biol Chem"},{"key":"9462_CR100","unstructured":"Pharmaceuticals A (2014) Phase 2 study to evaluate ALN-TTRSC in patients with transthyretin (TTR) cardiac amyloidosis"},{"issue":"5","key":"9462_CR101","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/mus.20503","volume":"33","author":"MD Benson","year":"2006","unstructured":"Benson MD et al (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33(5):609\u2013618","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"9462_CR102","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/13506129.2011.574354021","volume":"18","author":"MD Benson","year":"2011","unstructured":"Benson MD et al (2011) Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 18(Suppl 1):60","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"9462_CR103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/13506129.2012.673140","volume":"19","author":"EJ Ackermann","year":"2012","unstructured":"Ackermann EJ et al (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19(Suppl 1):43\u201344","journal-title":"Amyloid"},{"key":"9462_CR104","unstructured":"Pharmaceuticals, I (2013) Efficacy and safety of ISIS-TTRRx in familial amyloid polyneuropathy. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01737398?term=ISIS+amyloid&rank=1"},{"issue":"2","key":"9462_CR105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","volume":"20","author":"I Cardoso","year":"2006","unstructured":"Cardoso I, Saraiva MJ (2006) Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 20(2):234\u2013239","journal-title":"FASEB J"},{"key":"9462_CR106","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","volume":"8","author":"I Cardoso","year":"2010","unstructured":"Cardoso I et al (2010) Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 8:74","journal-title":"J Transl Med"},{"issue":"Suppl 1","key":"9462_CR107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","volume":"19","author":"L Obici","year":"2012","unstructured":"Obici L et al (2012) Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19(Suppl 1):34\u201336","journal-title":"Amyloid"},{"key":"9462_CR108","unstructured":"Matteo IPS (2011) Safety, efficacy and pharmacokinetics of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01171859?term=%EF%82%A7%09NCT01171859&rank=1"},{"key":"9462_CR109","unstructured":"Hospital, B.a.W.s. (2013) Tolerability and efficacy of a combination of doxycycline and TUDCA in patients with transthyretin amyloid cardiomyopathy. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01855360?term=NCT01855360&rank=1"},{"issue":"8020","key":"9462_CR110","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0140-6736(77)91260-0","volume":"1","author":"MB Pepys","year":"1977","unstructured":"Pepys MB, Dash AC (1977) Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet 1(8020):1029\u20131031","journal-title":"Lancet"},{"issue":"7320","key":"9462_CR111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K et al (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468(7320):93\u201397","journal-title":"Nature"},{"issue":"6886","key":"9462_CR112","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB et al (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417(6886):254\u2013259","journal-title":"Nature"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-014-9462-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-014-9462-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-014-9462-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:50:25Z","timestamp":1717570225000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-014-9462-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,19]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["9462"],"URL":"https:\/\/doi.org\/10.1007\/s10741-014-9462-7","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,19]]}}}